Bayer and Recursion entered a strategic collaboration leveraging Recursion's AI-driven phenomics drug discovery platform to develop new therapies for fibrosis (lung, kidney, heart). Recursion received $30M upfront from Bayer; Leaps by Bayer led a $50M Series D investment. Up to ten programs with $100M+ in milestones each plus royalties. Total potential value ~$1.1B+.
Key facts
AnnouncedSep 09, 2020
Deal value$1.1B
Deal typeCo-Development
Therapeutic areaFibrotic diseases of lung, kidney, heart
IndicationsFibrotic diseases of lung, kidney, heart
Key assetsAI-discovered small molecules from Recursion's phenomics platform